Central macular thickness Changes in Systemic Lupus erythematosus Patients on Hydroxychloroquine using Optical Coherence Tomography Angiography | ||||
Fayoum University Medical Journal | ||||
Volume 14, Issue 2, December 2024, Page 101-109 PDF (681.11 K) | ||||
Document Type: Full Length research Papers | ||||
DOI: 10.21608/fumj.2024.304628.1367 | ||||
![]() | ||||
Authors | ||||
Helana Samy Raafat ![]() | ||||
Department of Ophthalmology, Faculty of Medicine, Fayoum University, Fayoum, Egypt | ||||
Abstract | ||||
Background: Hydroxychloroquine (HCQ) is extensively utilized for the management of Systemic lupus erythematosus (SLE). HCQ retinopathy is a known and well-documented adverse impact of HCQ. This condition can be examined by optical coherence tomography angiography (OCTA). Aim of the study: To evaluate central macular thickness on OCTA in SLE patients who are receiving HCQ. Subjects and Methods: This study is an observational cross-sectional study that covered the right eyes of 90 individuals with systemic lupus erythematosus (SLE), which were divided into three groups. Group 1 consists of 30 patients who are not getting hydroxychloroquine (HCQ). Group 2 consists of 30 patients who were administered HCQ for a duration of less than 2 years. Group 3 consists of 30 patients who were administered HCQ for a duration exceeding 2 years. OCTA was conducted on all patients utilizing (Optovue, Inc., Fremont, CA, USA). Results: There was no statistical significant difference with p-value >0.05 between study groups regarding central macular thickness. There was no statistical significant correlation with p-value >0.05 between HCQ treatment duration and macular thickness. Conclusion: The central macular thickness in SLE patients on HCQ therapy utilizing OCTA did not show any notable alterations. | ||||
Keywords | ||||
Hydroxychloroquine; Systemic lupus erythematosus; optical coherence tomography angiography | ||||
Statistics Article View: 134 PDF Download: 117 |
||||